14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Aug 19, 2019 $0.315 $0.338 $0.300 $0.320 713 035
Aug 16, 2019 $0.300 $0.309 $0.290 $0.308 265 699
Aug 15, 2019 $0.303 $0.320 $0.260 $0.300 1 050 909
Aug 14, 2019 $0.298 $0.298 $0.250 $0.298 715 506
Aug 13, 2019 $0.299 $0.308 $0.298 $0.303 223 090
Aug 12, 2019 $0.300 $0.310 $0.298 $0.300 123 933
Aug 09, 2019 $0.305 $0.310 $0.290 $0.302 279 998
Aug 08, 2019 $0.293 $0.305 $0.291 $0.300 432 956
Aug 07, 2019 $0.315 $0.321 $0.280 $0.291 846 377
Aug 06, 2019 $0.311 $0.320 $0.300 $0.308 475 252
Aug 05, 2019 $0.325 $0.329 $0.305 $0.310 355 912
Aug 02, 2019 $0.310 $0.340 $0.305 $0.332 1 690 308
Aug 01, 2019 $0.327 $0.339 $0.305 $0.310 341 709
Jul 31, 2019 $0.320 $0.335 $0.310 $0.318 363 782
Jul 30, 2019 $0.316 $0.330 $0.305 $0.322 624 019
Jul 29, 2019 $0.313 $0.340 $0.305 $0.310 685 084
Jul 26, 2019 $0.310 $0.320 $0.305 $0.313 243 025
Jul 25, 2019 $0.348 $0.348 $0.295 $0.309 1 200 545
Jul 24, 2019 $0.300 $0.390 $0.300 $0.352 2 190 442
Jul 23, 2019 $0.320 $0.325 $0.300 $0.305 592 796
Jul 22, 2019 $0.328 $0.335 $0.301 $0.304 348 697
Jul 19, 2019 $0.330 $0.341 $0.320 $0.322 431 080
Jul 18, 2019 $0.328 $0.340 $0.312 $0.330 339 546
Jul 17, 2019 $0.320 $0.340 $0.298 $0.323 807 117
Jul 16, 2019 $0.328 $0.340 $0.315 $0.318 599 078
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT